Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Status:
Terminated
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
Panobinostat is a drug that may slow down the growth of cancer cells or kill cancer cells by
blocking certain enzymes. Panobinostat has shown effects against cancer in laboratory
studies. However, it is not known if it will show the same activity in humans. Panobinostat
has been given to participants with various types of cancers, including DLBCL, in previous
research studies. In this study panobinostat will be given with the the antibody rituximab,
which is FDA approved to be given with chemotherapy in DLBCL.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute